Mylan acamprosate calcium tablets recalled for failed dissolution
Mylan Pharmaceuticals is recalling one lot of Acamprosate Calcium 333 mg delayed-release tablets because they failed to meet dissolution specifications—meaning the tablets may not break down and release the medication as intended in the body. This could result in ineffective treatment. No injuries have been reported.
From the FDA notice · Read the official notice ↗ · All Mylan recalls
What to do
- Check if your Acamprosate Calcium matches lot #3227809 (expiring 10/2026, NDC 0378-6333-80).
- Contact your pharmacy or doctor if you have this lot; do not stop taking your medication without medical guidance.
- Your pharmacy or doctor can provide a replacement or alternative treatment.
Is yours affected?
Compare your label or packaging with the recalled product.
- Product
- Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80.
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Details
- Illnesses reported
- None reported
- Manufactured in
- 3711 Collins Ferry Rd, Morgantown, WV, United States
- Classification
- Class II
- Recall number
- D-0774-2026
In the FDA's words
- Description
- Acamprosate Calcium, Delayed-Release Tablets, 333 mg, 180 tablets bottles, Rx only, Mylan Pharmaceuticals Inc., Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 266505, NDC 0378-6333-80. Failed Dissolution Specifications Lot# 3227809; Expiry:10/2026; NDC #: 0378-6333-80 Distribution: US Nationwide.
- Hazard
- Failed Dissolution Specifications
More from Mylan
See all- Mylan prasugrel 10 mg tablets recalled for failed dissolution testing
ModerateFDASep 9, 2026
- Mylan Mycophenolate Mofetil injection recalled for failed dissolution specifications
ModerateFDASep 9, 2026